Brief: FDA Grants Pediatric Disease Designation For Mateon’s OT101
23/09/2019 14:17
Sept 23 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* FDA GRANTS PEDIATRIC DISEASE DESIGNATION FOR MATEON’S
OT101
Source text for Eikon: ID:nGNX5s0vNQ
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas